We propose that studies of differing design, such as very large‐scale case‐control sequencing studies able to detect rare variation, will be required to address if a low to moderate risk of cancer may be associated with BRCA1/2 regulatory region variation that has not been captured to date by genome‐wide association genotyping platforms. The gene discussed is BRCA1; the disease is cancer.